Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Tegazel is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage: In adult women under 65, the recommended dose is 6 mg orally, twice daily, taken at least 30 minutes before meals. If symptoms are not adequately controlled after 4 to 6 weeks of treatment, Tegaserod should be discontinued. Pediatric use: The safety and effectiveness of Tegaserod in pediatric patients have not been established. Geriatric use: Tegaserod is not indicated for use in patients aged 65 years or older. Renal impairment: Tegaserod should not be used in patients with severe renal impairment (eGFR below 15 mL/min/1.73 m2) or end-stage renal disease. Hepatic impairment: Tegaserod should not be used in patients with moderate or severe hepatic impairment.
Side Effects
The most common side effects (occurring in more than 2% of patients) include headache, abdominal pain, nausea, diarrhea, flatulence, dyspepsia, and dizziness.
Cautions & Contraindications
Warnings & Precautions
Cardiovascular Ischemic Events, Including Major Adverse Cardiovascular Events (MACE): Before starting treatment, patients and prescribers should weigh the possible cardiovascular risks against the expected improvement in IBS-C symptoms. Tegazel should be stopped at once if a patient has a heart attack, stroke, transient ischemic attack, or angina. If a patient shows signs of ischemic heart disease, or their overall health changes in a way that could raise cardiovascular risk while on treatment, the benefits and risks of continuing should be reassessed. Ischemic Colitis: Patients should be watched for rectal bleeding, bloody diarrhea, and abdominal pain that is new or getting worse. Tegazel should be discontinued if any of these symptoms appear. Volume Depletion Associated with Diarrhea: Tegazel should not be used in patients who have severe diarrhea. Patients should be told to stop taking Tegazel and contact their healthcare provider right away if they develop severe diarrhea, low blood pressure, or fainting. Suicidal Ideation and Behavior: Patients should be monitored for worsening depression and the emergence of suicidal thoughts or behavior, particularly in the first few months of treatment. They should be advised to stop Tegazel immediately and contact their healthcare provider if their depression persistently worsens or if new suicidal thoughts or behavior appear.
Contraindications
Tegaserod is contraindicated in patients with: A history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina A history of ischemic colitis or other forms of intestinal ischemia Severe renal impairment (eGFR< 15 mL/min/1.73 m2) or end-stage renal disease Moderate and severe hepatic impairment A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions Hypersensitivity to tegaserod.